NCT00630864 - The Effects of Fx-1006A on Transthyretin Stabilization and Clinical Outcome Measures in Patients With Non-V30M Transthyretin Amyloidosis | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 30, 2008

Primary Completion Date

January 31, 2010

Study Completion Date

January 31, 2010

Conditions

Transthyretin-associated Amyloidosis With Polyneuropathy

Interventions

DRUG

Fx-1006A

During Part 1, patients will receive Fx-1006A 20mg soft gelatin capsules once daily (at the same time each day) for two weeks. During Part 2, patients will receive Fx-1006A 20mg soft gelatin capsules once daily to complete a total of 12 months of dosing

Trial Locations (4)

21205

Johns Hopkins Hospital, Baltimore

Unknown

CHU de Bicetre, Paris

Universitatsklinikum Munster, Transplant Hepatology, Münster

19 - 27100

Centro per lo Studio e la Cura delle Amiloidosi Sistemiche, Irccs - Policlinico San Matteo